{"id":"placebo-once-weekly","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4594486","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Placebos are inert substances that have no therapeutic effect. They are used in clinical trials to serve as a baseline to compare against the effects of the actual drug being tested.","oneSentence":"A placebo does not have an active pharmacological mechanism; it is used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:16.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05241041","phase":"NA","title":"Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2021-09-13","conditions":"Gambling","enrollment":198},{"nctId":"NCT07046819","phase":"PHASE2","title":"Tirzepatide in MetALD","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder","enrollment":120},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT05318976","phase":"PHASE2","title":"A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation","status":"COMPLETED","sponsor":"Inmune Bio, Inc.","startDate":"2022-02-28","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":208},{"nctId":"NCT07495033","phase":"PHASE3","title":"Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-01","conditions":"CTD-ILD","enrollment":260},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":"Obesity With Diabetes, Overweight With Diabetes","enrollment":1700},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT06047548","phase":"PHASE3","title":"A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-20","conditions":"Overweight, Obesity","enrollment":441},{"nctId":"NCT06980805","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-02-19","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":56},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT07035093","phase":"PHASE3","title":"A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-29","conditions":"Obesity, Overweight, Chronic Low Back Pain (CLBP)","enrollment":586},{"nctId":"NCT06439277","phase":"PHASE3","title":"A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-06-03","conditions":"Obesity, Weight Gain","enrollment":300},{"nctId":"NCT06383390","phase":"PHASE3","title":"The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-30","conditions":"Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)","enrollment":10000},{"nctId":"NCT03835767","phase":"PHASE2","title":"Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-19","conditions":"Milk and/or Peanut Allergy","enrollment":200},{"nctId":"NCT06662539","phase":"PHASE2","title":"Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2024-12-09","conditions":"Obesity","enrollment":493},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT06979531","phase":"PHASE2","title":"Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-06-30","conditions":"Primary Sjögren's Syndrome","enrollment":180},{"nctId":"NCT07353931","phase":"PHASE3","title":"Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-09","conditions":"Osteoarthritis, Overweight or Obesity","enrollment":900},{"nctId":"NCT07282600","phase":"PHASE3","title":"A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-15","conditions":"Overweight, Obesity","enrollment":1035},{"nctId":"NCT07369011","phase":"PHASE3","title":"A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-10","conditions":"Sleep Apnea, Obstructive, Obesity, Overweight","enrollment":800},{"nctId":"NCT07392190","phase":"PHASE3","title":"A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-10","conditions":"Overweight, Obesity","enrollment":900},{"nctId":"NCT07281495","phase":"PHASE2","title":"Taldefgrobep Alfa in Adults With Overweight and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2025-11-24","conditions":"Obesity, Overweight","enrollment":150},{"nctId":"NCT07321886","phase":"PHASE3","title":"A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-06","conditions":"Obesity, Overweight","enrollment":1980},{"nctId":"NCT07232719","phase":"PHASE3","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-17","conditions":"Obesity, Overweight","enrollment":250},{"nctId":"NCT06465108","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism","status":"COMPLETED","sponsor":"MBX Biosciences","startDate":"2024-08-08","conditions":"Hypoparathyroidism","enrollment":64},{"nctId":"NCT06077864","phase":"PHASE3","title":"A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-11-20","conditions":"Obesity","enrollment":5531},{"nctId":"NCT07481578","phase":"NA","title":"Impact of Training Load on the Gut miCrobiome And Its Relation to exeRcise Performance, mUscle Phenotype, and markerS of Overreaching in Healthy Men","status":"RECRUITING","sponsor":"Stefan De Smet","startDate":"2024-10-07","conditions":"Exercise, Overreaching, Butyrate","enrollment":45},{"nctId":"NCT07481630","phase":"PHASE3","title":"A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-04-13","conditions":"Obesity, Knee Osteoarthritis (OA)","enrollment":400},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT06632457","phase":"PHASE3","title":"LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-11-07","conditions":"Metabolic Dysfunction Associated Steatohepatitis","enrollment":1590},{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","enrollment":2539},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT06066528","phase":"PHASE3","title":"A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-11-27","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT06455449","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-20","conditions":"Polymyositis, Dermatomyositis","enrollment":240},{"nctId":"NCT07282743","phase":"PHASE2","title":"Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2026-01-20","conditions":"Type II Diabetes Mellitus","enrollment":285},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT05741710","phase":"PHASE1, PHASE2","title":"A Study to Assess the Use of Methylone in the Treatment of PTSD","status":"COMPLETED","sponsor":"Transcend Therapeutics","startDate":"2023-03-01","conditions":"Post Traumatic Stress Disorder","enrollment":79},{"nctId":"NCT07351058","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight, Type 2 Diabetes Mellitus","enrollment":1600},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07351045","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight","enrollment":2000},{"nctId":"NCT05925803","phase":"PHASE3","title":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-08","conditions":"Systemic Sclerosis, Scleroderma","enrollment":314},{"nctId":"NCT05912517","phase":"PHASE3","title":"A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Hemolytic Disease of the Fetus and Newborn","enrollment":120},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":"Obesity","enrollment":1200},{"nctId":"NCT04838301","phase":"PHASE2","title":"Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-08-15","conditions":"Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases","enrollment":100},{"nctId":"NCT07469800","phase":"PHASE3","title":"Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-04-01","conditions":"Overweight, Obesity, Hypertensive","enrollment":336},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT07456696","phase":"PHASE3","title":"An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)","status":"RECRUITING","sponsor":"Transcend Therapeutics","startDate":"2026-03","conditions":"Post Traumatic Stress Disorder","enrollment":300},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07400107","phase":"PHASE3","title":"AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-05-20","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":1000},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT06066515","phase":"PHASE3","title":"A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-11-25","conditions":"Obesity","enrollment":726},{"nctId":"NCT05669755","phase":"PHASE3","title":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-03-01","conditions":"Cardiovascular Disease","enrollment":7101},{"nctId":"NCT05227742","phase":"EARLY_PHASE1","title":"Exploratory Study of Low Dose Psilocybin","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-15","conditions":"Demoralization","enrollment":""},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT07463846","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ALN-2232 in Participants With Obesity","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2026-03-02","conditions":"Obesity","enrollment":156},{"nctId":"NCT03811561","phase":"PHASE3","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-05-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1500},{"nctId":"NCT07415954","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-04-17","conditions":"Diabetes Mellitus, Type 2","enrollment":270},{"nctId":"NCT07458269","phase":"PHASE2","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-03","conditions":"Obesity","enrollment":250},{"nctId":"NCT07455006","phase":"PHASE3","title":"Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-20","conditions":"Thrombocytopenia, Immune","enrollment":60},{"nctId":"NCT05371496","phase":"PHASE2","title":"Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2022-09-06","conditions":"Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity","enrollment":81},{"nctId":"NCT07039916","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-05-27","conditions":"Generalized Myasthenia Gravis","enrollment":231},{"nctId":"NCT06722235","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-27","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":171},{"nctId":"NCT07220759","phase":"PHASE3","title":"Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-05","conditions":"Overweight, Obesity, Type 2 Diabetes","enrollment":330},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT06354660","phase":"PHASE3","title":"Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-10","conditions":"Diabetes Type 2","enrollment":537},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT05835752","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of RAY1225","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-05-18","conditions":"Obese, Healthy","enrollment":68},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT07448974","phase":"PHASE3","title":"Vitamin D and Type 2 Diabetes - Treat-To-Target","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-05","conditions":"Prediabetes, Type 2 Diabetes (T2DM)","enrollment":100},{"nctId":"NCT07449351","phase":"EARLY_PHASE1","title":"Psilocybin Microdosing on Cognition, Mood and Quality of Life","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04-01","conditions":"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI","enrollment":20},{"nctId":"NCT07339423","phase":"PHASE3","title":"AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-02-24","conditions":"Obesity","enrollment":1150},{"nctId":"NCT05407324","phase":"PHASE2","title":"Dazucorilant in Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2022-11-15","conditions":"Amyotrophic Lateral Sclerosis","enrollment":279},{"nctId":"NCT05819138","phase":"PHASE3","title":"Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-21","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT06897475","phase":"PHASE2","title":"A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-28","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07284875","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-18","conditions":"Obesity, Overweight","enrollment":1800},{"nctId":"NCT06610487","phase":"PHASE1","title":"A Study of FT1 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2024-08-20","conditions":"Diarrhea Caused by Drug (Disorder)","enrollment":60},{"nctId":"NCT06465186","phase":"PHASE2","title":"A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-12","conditions":"Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD","enrollment":80},{"nctId":"NCT07435610","phase":"NA","title":"Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction","status":"RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2026-01-08","conditions":"Disorders of Gut-brain Interaction","enrollment":96},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT06892288","phase":"PHASE2, PHASE3","title":"A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glycomine, Inc.","startDate":"2025-07-09","conditions":"Phosphomannomutase 2 Deficiency, PMM2-CDG","enrollment":50},{"nctId":"NCT06993155","phase":"PHASE2","title":"A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function","status":"RECRUITING","sponsor":"ReproNovo Aps","startDate":"2025-06-27","conditions":"Semen Quality","enrollment":200},{"nctId":"NCT07435636","phase":"PHASE2","title":"Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis","status":"NOT_YET_RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2026-04-13","conditions":"Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis","enrollment":80},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07434050","phase":"PHASE3","title":"A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2026-03-09","conditions":"OSA - Obstructive Sleep Apnea, Obesity","enrollment":140},{"nctId":"NCT06841536","phase":"NA","title":"Combined Effects of Statins and Exercise on Training Sensitive Health Markers","status":"COMPLETED","sponsor":"University of the Faroe Islands","startDate":"2025-05-01","conditions":"Dyslipidemias","enrollment":120},{"nctId":"NCT07220642","phase":"PHASE3","title":"Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-05","conditions":"Obesity, Overweight","enrollment":300},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT05891496","phase":"PHASE3","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-20","conditions":"Alzheimers Disease","enrollment":23},{"nctId":"NCT05528705","phase":"NA","title":"Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome","status":"COMPLETED","sponsor":"Green Cross Wellbeing","startDate":"2022-09-13","conditions":"Shoulder Impingement Syndrome","enrollment":50},{"nctId":"NCT03878589","phase":"PHASE2, PHASE3","title":"Understanding Cognition, Oxytocin & Pain in Elders","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-08-06","conditions":"Knee Osteoarthritis, Osteoarthritis","enrollment":83},{"nctId":"NCT05303701","phase":"PHASE3","title":"GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)","status":"NOT_YET_RECRUITING","sponsor":"Samsung Pharmaceutical Co., Ltd.","startDate":"2027-07","conditions":"Moderate to Severe Alzheimer's Disease","enrollment":750},{"nctId":"NCT06137365","phase":"PHASE2","title":"Cannabis for Obesity Trial","status":"NOT_YET_RECRUITING","sponsor":"Joshua A. Lile, Ph.D.","startDate":"2026-04-01","conditions":"Obesity","enrollment":40},{"nctId":"NCT06079398","phase":"PHASE2","title":"A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia","status":"RECRUITING","sponsor":"Ascendis Pharma A/S","startDate":"2024-01-23","conditions":"Achondroplasia","enrollment":72},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo once weekly","genericName":"placebo once weekly","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}